Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

1,195

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

October 31, 2012

Conditions
Prostatic Neoplasms
Interventions
DRUG

Placebo

Four tablets once daily until disease progression

DRUG

Abiraterone acetate

Four 250-mg tablets once daily until disease progression

DRUG

Prednisone/prednisolone

5 mg twice daily until disease progression

Trial Locations (127)

Unknown

Birmingham

Tucson

Beverly Hills

Duarte

Los Angeles

Marina del Rey

Sacramento

San Diego

San Francisco

Aurora

Bristol

New Haven

Stamford

Boca Raton

Fort Lauderdale

Fort Myers

West Palm Beach

Atlanta

Honolulu

Chicago

Galesburg

Indianapolis

Westwood

Wichita

Marrero

New Orleans

Baltimore

Boston

Detroit

Robbinsdale

St Louis

Billings

Omaha

Las Vegas

Box 302

East Setauket

New Hyde Park

New York

Stony Brook

Durham

Raleigh

Canton

Cincinnati

Portland

Philadelphia

Pittsburgh

Myrtle Beach

Chattanooga

Nashville

Dallas

Houston

San Antonio

Virgiania Beach

Seattle

Adelaide

Camperdown

Footscray

Geelong

Heidelberg

Herston

Hobart

Hornsby

Kogarah

Kurralta Park

Liverpool

Milton

Parkville

Perth

Subiaco

Wodonga

Wollongong

Linz

Salzburg

Vienna

Antwerp

Bonheiden

Brussels

Ghent

Hasselt

Kortrijk

Leuven

Liège

Roeselare

Edmonton

Kelowna

Vancouver

Victoria

Halifax

Hamilton

Toronto

Montreal

Regina

Calgary Ab

London

Angers

Caen

Cannes

Dijon

Lyon

Paris

Saint-Herblain

Vandœuvre-lès-Nancy

Villejuif

Aachen

Berlin

Dresden

Hamburg

Homburg/Saar

Pécs

Szombathely

Cork

Dublin

Nijmegen

Badalona

Barcelona

Madrid

Belfast

Birmingham

Cambridge

Glasgow

London

Manchester

Newcastle upon Tyne

Northwood

Oxford

Sutton

Whitchurch

Sponsors
All Listed Sponsors
lead

Cougar Biotechnology, Inc.

INDUSTRY